Clinical trialNCT01662102TerminatedPhase 3Interventional

Rituximab or Zevalin - Efficacy Trial of Therapeutic Alternatives (RoZetta)

SponsorSpectrum Pharmaceuticals, IncEnrollment1Follicular Lymphoma

View the registry record on ClinicalTrials.gov

Summary

The lay summary the sponsor registered on ClinicalTrials.gov.

The purpose of this study is to evaluate the effect of consolidation treatment Zevalin® versus maintenance treatment with Rituxan® on progression-free survival (PFS) following response induction with chemotherapy plus rituximab in previously untreated participants with follicular lymphoma.

clinicaltrials.gov ↗

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

Fernando Cabanillas, MD
M.D. Anderson Cancer Center
Principal Investigator
clinicaltrials.gov ↗
Leonard Klein, MD
Illinois Cancer Specialists - US Oncology
Principal Investigator
clinicaltrials.gov ↗
Petros Nikolinakos, MD
Northeast Georgia Cancer Care
Principal Investigator
clinicaltrials.gov ↗
Steven E Finkelstein, MD
GenesisCare USA
Principal Investigator
clinicaltrials.gov ↗
Steven Jubelirer, MD
West Virginia University
Principal Investigator
clinicaltrials.gov ↗
Thomas Witzig, MD
The Mayo Clinic & Foundation
Principal Investigator
clinicaltrials.gov ↗

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

5 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States

21st Century Oncology
Sun City, Arizona, United States
Northeast Georgia Cancer Care
Athens, Georgia, United States
Illinois Cancer Specialists
Niles, Illinois, United States
Park Nicollet Institute
Saint Louis Park, Minnesota, United States
Charleston Area Medical Center
Charleston, West Virginia, United States

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Rituximab →Zevalin

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start: 11 Dec 2012
Primary completion: 5 Mar 2013
Completion: 5 Mar 2013
Last update posted: 4 Oct 2021
Registered enrollment: 1
Registry id: NCT01662102

clinicaltrials.gov ↗

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 24 Aug 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.